查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1917753

睡眠障礙治療市場－2026-2031年預測

Sleep Disorder Treatment Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 148 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計睡眠障礙治療市場將從 2025 年的 198.78 億美元成長到 2031 年的 356.66 億美元，複合年成長率為 10.23%。

由於全球失眠和其他睡眠障礙的發生率不斷上升，睡眠障礙治療市場需求日益成長。憂鬱症、焦慮症和心理創傷發病率的上升，以及飲酒和氣喘導致的睡眠模式紊亂，進一步推動了市場成長。透過睡眠健康宣傳活動和教育活動意識提升，也促進了市場的發展勢頭。

睡眠障礙的治療方法因病因而異，通常包括藥物治療、生活方式調整和飲食習慣改變。主要促進因素包括某些藥物相關睡眠障礙病例的增加以及頻尿等因素。未經治療的睡眠問題所帶來的副作用，例如嗜睡和易怒，凸顯了有效治療方法的必要性，並推動了市場擴張。

關鍵成長要素包括憂鬱症和焦慮症的日益普遍（其中失眠通常是核心症狀），以及由心理和生理創傷和合併症引起的睡眠障礙，這些因素也推動了對有針對性的治療方法的需求。

氣喘病例的增加和酒精消費量的成長也推動了市場成長。氣喘藥物及其相關併發症會加劇失眠，而過量飲酒則會損害睡眠的數量和質量，從而經常導致失眠。

由於睡眠障礙的高發生率以及公眾對其危害的日益關注，存在著許多機會。持續的宣傳活動在促進治療方法普及方面發揮著至關重要的作用。例如，睡眠基金會已連續25年舉辦“睡眠意識週®”，旨在傳播睡眠模式數據以及基於實證的睡眠對健康影響指導。此外，生活水準的提高和人們健康意識的增強也擴大了市場潛力，並為創新和新進入者創造了機會。

從地理上看，北美預計在預測期內將保持顯著的市場佔有率。這一主導地位主要得益於較高的疾病認知度和診斷率，以及快節奏的生活方式所導致的壓力和睡眠問題。此外，主要行業參與者的存在，透過提供先進的治療方案和便利的醫療服務，進一步推動了該地區的成長。

睡眠障礙治療領域的主要企業包括輝瑞公司，該公司致力於推動醫療創新，並提供適用於各年齡層睡眠障礙的Sonata®（Zaleplon）膠囊等產品。總部位於日本的全球研發主導企業武田藥品工業株式會社提供獲得美國食品藥品監督管理局（FDA）核准的非處方睡眠藥物Rozerem™，該藥物選擇性地靶向大腦視交叉上核（SCN）中的受體。

總體而言，市場正在迅速擴張，透過多方面的方法解決睡眠健康方面的關鍵缺口，將藥物解決方案與行為和教育策略相結合，以應對人口結構和生活方式變化帶來的挑戰。

本報告的主要優勢：

  • 深入分析：取得以客戶群、政府政策和社會經濟因素、消費者偏好、垂直產業和其他細分市場為重點的深入市場洞察，涵蓋主要地區和新興地區。
  • 競爭格局：了解主要企業採取的策略舉措，並了解透過正確的策略實現市場滲透的潛力。
  • 市場促進因素與未來趨勢：探索動態因素和關鍵市場趨勢，以及它們將如何塑造未來的市場發展。
  • 可執行的建議：利用洞察力為策略決策提供訊息，從而在動態環境中開拓新的業務管道和收入來源。
  • 受眾範圍廣：對新興企業、研究機構、顧問公司、中小企業和大型企業都有益處且經濟高效。

它是用來做什麼的？

產業與市場洞察、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範及其影響、新產品開發、競爭影響

分析範圍

  • 歷史資料（2021-2025 年）和預測資料（2026-2031 年）
  • 成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
  • 競爭對手定位、策略和市場佔有率分析
  • 按業務板塊和地區（國家）分類的收入成長和預測分析
  • 公司概況（策略、產品、財務資訊、關鍵趨勢等）

目錄

第1章執行摘要

第2章市場概述

  • 市場概覽
  • 市場定義
  • 分析範圍
  • 市場區隔

第3章 商業情境

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 波特五力分析
  • 產業價值鏈分析
  • 政策和法規
  • 策略建議

第4章 技術展望

第5章：按藥物類型分類的睡眠障礙治療市場

  • 介紹
  • 苯二氮平類藥物
  • 非苯二氮平類藥物
  • 抗憂鬱症
  • Orexin拮抗劑
  • 褪黑素拮抗劑
  • 其他藥物類型

第6章：按應用分類的睡眠障礙治療市場

  • 介紹
  • 失眠
  • 睡眠呼吸中止症
  • 嗜睡症
  • 晝夜節律紊亂
  • 其他用途

第7章 按支付方分類的睡眠障礙治療市場

  • 介紹
  • 公共醫療保險
  • 私人醫療保險

8. 各地區睡眠障礙治療市場

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 印尼
    • 泰國
    • 其他

第9章 競爭格局與分析

  • 主要企業和策略分析
  • 市佔率分析
  • 企業合併、協議、商業合作
  • 競爭對手儀錶板

第10章：公司簡介

  • Dr Reddy's Laboratory
  • Merck & Co.
  • Pfizer
  • Sanofi SA
  • Takeda Pharmaceuticals Inc.
  • Teva Pharmaceuticals Inc.
  • Vanda Pharmaceuticals Inc.
  • Sleep Health Solutions
  • Cleveland Clinic
  • Mayo Clinic

第11章附錄

  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要收益
  • 分析方法
  • 簡稱
簡介目錄
Product Code: KSI061615712

The sleep disorder treatment market is forecasted to achieve a 10.23% CAGR, reaching USD 35.666 billion in 2031 from USD 19.878 billion in 2025.

The sleep disorder treatment market is witnessing rising demand driven by increasing prevalence of insomnia and other sleep disturbances worldwide. Growth is further fueled by higher rates of depression, anxiety, and psychological trauma, alongside disruptions to sleep patterns from alcohol consumption and asthma. Expanding public awareness through dedicated sleep health campaigns and educational initiatives is also contributing to market momentum.

Treatments for sleep disorders vary based on underlying causes and typically combine medical interventions with lifestyle and dietary modifications. Key drivers include escalating sleep disorder cases linked to factors such as certain medications and frequent urination. The adverse effects of untreated sleep issues, including drowsiness and irritability, underscore the need for effective therapies, propelling market expansion.

A significant growth driver is the growing prevalence of depression and anxiety, where insomnia often manifests as a core symptom. Sleep disruptions can also stem from psychological or physical trauma and comorbid health conditions, positively influencing demand for targeted treatments.

Rising asthma cases and alcohol consumption further accelerate market growth. Asthma medications and associated comorbidities can exacerbate insomnia, while excessive alcohol intake impairs both sleep quantity and quality, frequently leading to insomnia.

Opportunities abound due to the high prevalence of sleep disorders and heightened public awareness of their detrimental effects. Ongoing awareness programs play a pivotal role in driving adoption of treatments. For instance, the Sleep Foundation has organized Sleep Awareness Week(R) annually for over 25 years, disseminating data on sleep patterns and evidence-based guidance on its health impacts. Additionally, rising living standards and greater health consciousness among populations are augmenting market potential, creating avenues for innovation and entry.

Geographically, North America is anticipated to maintain a significant market share during the forecast period. This dominance is supported by elevated disease awareness and diagnosis rates, coupled with demanding lifestyles that contribute to stress and sleep issues. The presence of major industry players further bolsters regional growth through advanced therapeutic options and accessibility.

Leading companies in the sleep disorder treatment sector include Pfizer, which advances medical innovation with offerings such as Sonata(R) (zaleplon) capsule CIV, suitable for sleep disturbances across younger and elderly demographics. Takeda Pharmaceuticals, a global research-driven entity based in Japan, provides Rozerem(TM), an FDA-approved non-scheduled prescription sleep medication that selectively targets receptors in the brain's suprachiasmatic nucleus (SCN).

Overall, the market is expanding rapidly, addressing critical gaps in sleep health through a multifaceted approach that integrates pharmacological solutions with behavioral and educational strategies, amid evolving demographic and lifestyle challenges.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Sleep Disorder Treatment Market Segmentation

  • By Drug Type
  • Benzodiazepines
  • Nonbenzodiazepines
  • Antidepressants
  • Orexin Antagonists
  • Melatonin Antagonists
  • Other Drug Types
  • By Application
  • Insomnia
  • Sleep Apnea
  • Narcolepsy
  • Circadian Disorders
  • Other Applications
  • By Payor
  • Public Health Insurance
  • Private Health Insurance
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. SLEEP DISORDER TREATMENT MARKET BY DRUG TYPE

  • 5.1. Introduction
  • 5.2. Benzodiazepines
  • 5.3. Nonbenzodiazepines
  • 5.4. Antidepressants
  • 5.5. Orexin Antagonists
  • 5.6. Melatonin Antagonists
  • 5.7. Other Drug Types

6. SLEEP DISORDER TREATMENT MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Insomnia
  • 6.3. Sleep Apnea
  • 6.4. Narcolepsy
  • 6.5. Circadian Disorders
  • 6.6. Other Applications

7. SLEEP DISORDER TREATMENT MARKET BY PAYOR

  • 7.1. Introduction
  • 7.2. Public Health Insurance
  • 7.3. Private Health Insurance

8. SLEEP DISORDER TREATMENT MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Dr Reddy's Laboratory
  • 10.2. Merck & Co.
  • 10.3. Pfizer
  • 10.4. Sanofi SA
  • 10.5. Takeda Pharmaceuticals Inc.
  • 10.6. Teva Pharmaceuticals Inc.
  • 10.7. Vanda Pharmaceuticals Inc.
  • 10.8. Sleep Health Solutions
  • 10.9. Cleveland Clinic
  • 10.10. Mayo Clinic

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations